These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28669739)

  • 1. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.
    Caritis SN; Bastian JR; Zhang H; Kalluri H; English D; England M; Bobby S; Venkataramanan R
    Am J Obstet Gynecol; 2017 Oct; 217(4):459.e1-459.e6. PubMed ID: 28669739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.
    Bastian JR; Chen H; Zhang H; Rothenberger S; Tarter R; English D; Venkataramanan R; Caritis SN
    Am J Obstet Gynecol; 2017 Jan; 216(1):64.e1-64.e7. PubMed ID: 27687214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.
    Zhang H; Bastian JR; Zhao W; Chen H; Shaik IH; Chaphekar N; Caritis SN; Venkataramanan R
    Ther Drug Monit; 2020 Apr; 42(2):264-270. PubMed ID: 31929398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis.
    Zhang H; Kalluri HV; Bastian JR; Chen H; Alshabi A; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2018 Sep; 84(9):2075-2087. PubMed ID: 29873094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
    Haasen C; Linden M; Tiberg F
    J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple dosing with high doses of buprenorphine: Withdrawal and plasma concentrations.
    Hvittfeldt E; Charlotte G; Fridolf I; Håkansson A
    J Opioid Manag; 2015; 11(4):319-24. PubMed ID: 26312959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection.
    Hakomäki H; Kokki H; Lehtonen M; Ranta VP; Räsänen J; Voipio HM; Kokki M
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00726. PubMed ID: 33619904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.
    Kuhlman JJ; Levine B; Johnson RE; Fudala PJ; Cone EJ
    Addiction; 1998 Apr; 93(4):549-59. PubMed ID: 9684393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.
    Concheiro M; Jones HE; Johnson RE; Choo R; Huestis MA
    Ther Drug Monit; 2011 Oct; 33(5):619-26. PubMed ID: 21860340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1199-1210. PubMed ID: 28536980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
    Chiang CN; Hawks RL
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.
    Walsh SL; Comer SD; Zdovc JA; Sarr C; Björnsson M; Strandgården K; Hjelmström P; Tiberg F
    Neuropsychopharmacology; 2024 May; 49(6):1050-1057. PubMed ID: 38200140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
    Compton P; Ling W; Moody D; Chiang N
    Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms.
    Chawarski MC; Moody DE; Pakes J; O'Connor PG; Schottenfeld RS
    J Subst Abuse Treat; 2005 Dec; 29(4):307-12. PubMed ID: 16311183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine for the treatment of opioid dependence in pregnancy.
    Mittal L
    J Perinat Neonatal Nurs; 2014; 28(3):178-84. PubMed ID: 25062519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder.
    Seal KH; Maguen S; Bertenthal D; Batki SL; Striebel J; Stein MB; Madden E; Neylan TC
    J Clin Psychiatry; 2016 Sep; 77(9):1182-1188. PubMed ID: 27035058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.
    Amass L; Kamien JB; Mikulich SK
    Drug Alcohol Depend; 2001 Jan; 61(2):173-81. PubMed ID: 11137282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
    Marsch LA; Bickel WK; Badger GJ; Jacobs EA
    Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.